Posterior reversible encephalopathy syndrome (PRES) is a relatively rare neurotoxic disorder. A 56-year-old male underwent elective coronary angiography. A Few hours postprocedure, the patient developed bilateral painless vision loss, headache, vomiting and hypertension and was subsequently diagnosed with PRES. Possible trigger factors could be contrast agent used, or hypertension. Contrast agent–induced PRES in hypertensive patients is benign and reversible, and a high-grade suspicion about this possibility is critical for precise management. Our patient was successfully treated with supportive management and was doing well on follow-up.
HincheyJChavesCAppignaniBet al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med1996; 334: 494–500.
2.
FugateJEClaassenDOCloftHJet al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc2010; 85: 427–32.
3.
LeongSFanningNF (2012) Persistent neurological deficit from iodinated contrast encephalopathy following intracranial aneurysm coiling: a case report and review of the literature. Interv Neuroradiol18: 33–41.
4.
GaoBLyuCLernerAet al. Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?J Neurol Neurosurg Psychiatry2018; 89: 14–20.
5.
TorvikAWaldayP.Neurotoxicity of water-soluble contrast media. Acta Radiol Suppl1995; 399: 221–9.
6.
FugateJERabinsteinAA.Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol2015; 14: 914–25.
7.
BartynskiW.Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol2008; 29: 1036–42.
8.
McKinneyAMShortJTruwitCLet al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol2007; 189: 904–12.
9.
GranataGGrecoAIannellaGet al. Posterior reversible encephalopathy syndrome–insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev2015; 14: 830–6.
10.
UlasTBuyukhatipogluHDalMSet al. Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions. J Res Med Sci2013; 18: 205–9.
